Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011

Vaccine

Volumn 31, Issue 49, 2013, Pages 5863-5871

  Rudnick, Wallis ^a,b   Liu, Zhong ^a,b   Shigayeva, Altynay ^a   Low, Donald E ^a,b   Green, Karen ^a   Plevneshi, Agron ^a   Devlin, Roslyn ^b,c   Downey, James ^b,d   Katz, Kevin ^b,e   Kitai, Ian ^b,f   Krajden, Sigmund ^b,g   Ostrowska, Krystyna ^b,h   Richardson, David ^b,i   Richardson, Susan ^b,j   Sarabia, Alicia ^b,h   Silverman, Michael ^b,k   Simor, Andrew E ^b,l   Tyrrell, Gregory ^m   McGeer, Allison ^a,b   Allard, Susan ⁿ   Armstrong, Irene ^o   Yaffe, Barbara ^o   Baqi, Mahin ^p   Chen, Danny K ^q,r   Deeks, Shel ley ^s   Gubbay, Jonathan ^s   Jamieson, Frances ^s   Demczuk, Walter H B ^t   Martin, Irene ^t   de Villa, Eileen ^u   Dooling, Kath leen ^u   Gold, Wayne ^v   Walmsley, Sharon ^v   Kapala, Julius ^w   Johnstone, Jennie ^g   Lee, King S ^x   Loeb, Mark ^y   Smaill, Fiona ^y   Lovgren, Marguerite ^z,aa   Lovinsky, Reena ^ab   Rose, David ^ab   Ma, Charlotte ^a   Pong Porter, Sylvia ^a   Willey, Barbara ^a   Wong, Kenny ^a   Matlow, Anne G ^j   Tran, Dat ^j   Mederski, Barbara ^e   Muller, Matthew ^c   O'Grady, Sharon ^ac   Powis, Jeffrey E ^d   Rodger, Jennifer ^ad   Rau, Neil ^q   Sales, Valerie ^ae   Shokry, Phoebe ^ae   Vearncombe, Mary ^l   Yamamura, Deborah ^af,ag   more..

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d TORONTO EAST GENERAL HOSPITAL   (Canada)

^e NORTH YORK GENERAL HOSPITAL   (Canada)

^f Rouge Valley Health System   (Canada)

^g ST JOSEPH S HEALTH CENTRE   (Canada)

^h CREDIT VALLEY HOSPITAL   (Canada)

ⁱ WILLIAM OSLER HEALTH SYSTEM   (Canada)

^j HOSPITAL FOR SICK CHILDREN   (Canada)

^k LAKERIDGE HEALTH CORPORATION   (Canada)

^l SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^m Provincial Public Health Laboratory   (Canada)

ⁿ Joseph Brant Memorial Hospital Burlington   (Canada)

^o CITY OF TORONTO   (Canada)

^p William Osler Health System   (Canada)

^q William Osler HealthSystem ^*  (Canada)

^r ANIMAL HEALTH TRUST   (United Kingdom)

^s Disease Control Services   (Canada)

^t PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^u Z Tech (Canada) Inc   (Canada)

^v UNIVERSITY HEALTH NETWORK   (Canada)

^w DYNACARE LABORATORIES   (Canada)

^x HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^y HAMILTON HEALTH SCIENCES   (Canada)

^z National Centre for Streptococcus   (Canada)

^aa Alberta Provincial Health Laboratory   (Canada)

^ab SCARBOROUGH HOSPITAL   (Canada)

^ac Bridgepoint Health   (Canada)

^ad Royal Victoria Hospital Barrie   (Canada)

^ae MARKHAM STOUFFVILLE HOSPITAL   (Canada)

^af LifeLabs   (Canada)

^ag MCMASTER UNIVERSITY   (Canada)

more..

Author keywords

Case fatality; Invasive pneumococcal disease; Vaccination programs

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; BACTEREMIA; CANADA; CHILD; FATALITY; FEMALE; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MORBIDITY; MORTALITY; NURSING HOME; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; SMOKING; VACCINATION;

CASE FATALITY; INVASIVE PNEUMOCOCCAL DISEASE; VACCINATION PROGRAMS;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; ONTARIO; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84887618324     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.049     Document Type: Article

References (51)

1. O'Brien K.L., Wolfson L.J., Watt J.P., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2012, 374(9693):893-902.
2. Blasi F., Mantero M., Santus P., Tarsia P. Understanding the burden of pneumococcal disease in adults. Clinical Microbiology and Infection 2012, 18(Suppl. 5):7-14.
3. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2003, 378(9807):1962-1973.
4. Miller E., Andrews N.J., Waight P.A., Slack M.P.E., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infectious Diseases 2011, 11(10):760-768.
5. Vestrheim D.F., Høiby E.A., Bergsaker M.R., Rønning K., Aaberge I.S., Caugant D.A. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 2010, 28(10):2214-2221.
6. Al-Sukhni W., Avarino P., McArthur M.A., McGeer A. Impact of public vaccination programs on adult vaccination rates: two examples from Ontario, Canada. Vaccine 2008, 26(11):1432-1437.
7. Krueger P., St Amant O., Loeb M. Predictors of pneumococcal vaccination among older adults with pneumonia: findings from the community acquired pneumonia impact study. BMC Geriatrics 2010, 10(June 30):44.
8. Jaakkimainen L., Klein-Geltink J.E., Guttmann A., Barnesley J., Zagorski B.M., Kopp A., et al. Indicators of primary care based on administrative data. Primary care in Ontario 2006, ICES Atlas, Toronto, chapter 12. L. Jaakkimainen, R. Upshur, J.E. Klein-Geltink, A. Leong, S. Maaten, S.E. Schultz, L. Wang (Eds.).
9. Guttmann A., Manuel D., Dick P.T., To T., Lam K., Stukel T.A. Volume matters physician practice characteristics and immunization coverage among young children insured through a universal health plan. Pediatrics 2006, 117:595-602.
10. Statistics Canada Estimates of population by census division, sex and age group based on the Standard Geographical Classification (SGC) 2006, annual (persons) 2006, Statistics Canada, Available at: http://wwwstatcangcca/pub/ [accessed 11.02.13/12].
11. Spellerberg B., Brandt C. Streptococcus. Manual of clinical microbiology 2011, 405-421. American Society for Microbiology Press, Washington, DC. 10th ed. J. Versalovic, K.C. Carroll, G. Funke, J.H. Jorgensen, M.L. Landry, D.W. Warnock (Eds.).
12. Slotved H.-C., Kaltoft M., Skovsted I.C., Kerrn M.B., Espersen F. Simple, rapid latex agglutination test for serotyping of pneumococci (Pneumotest-Latex). Journal of Clinical Microbiology 2004, 42(6):2518-2522.
13. Austrian R. The Quellung reaction, a neglected microbiologic technique, New York. Mount Sinai journal of Medicine 1976, 43(6):699-709.
14. NACI The National Advisory Committee on Immunization, The Canadian Immunization Guide 2013, The Public Health Agency of Canada (PHAC), Ottawa, Canada, Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci [accessed 13.02.13].
15. Broome C., Facklam R., Fraser D. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. New England Journal of Medicine 1980, 303(10):549-552.
16. van Hoek A.J., Andrews N., Waight P.A., George R., Miller E. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes 1. PLoS ONE 2012, 7(7):e39150.
17. Weinberger D.M., Harboe Z.B., Sanders E.A., et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clinical Infectious Diseases 2010, 51(6):692-699.
18. Pilishvili T., Lexau C., Farley M.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Journal of Infectious Diseases 2010, 201(1):32-41.
19. Kellner J.D., Vanderkooi O.G., MacDonald J., Church D.L., Tyrrell G.J., Scheifele D.W. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clinical Infectious Diseases 2009, 49(2):205-212.
20. Andrews R.M., Counahan M.L., Hogg G.G., McIntyre P.B. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine 2004, 23(2):132-138.
21. Spindler C., Hedlund J., Jasir A., Normark B.H., Örtqvist Å. Effects of a large-scale introduction of the pneumococcal polysaccharide vaccine among elderly persons in Stockholm, Sweden. Vaccine 2008, 26(43):5541-5546.
22. Mooney J., Weir A., McMenamin J., et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infectious Diseases 2008, 8(1):53.
23. Andrews N.J., Waight P.A., George R.C., Slack M.P., Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine 2012, 30(48):6802-6808.
24. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ, Canadian Medical Association Journal 2009, 180(1):48-58.
25. Shapiro E.D., Berg A.T., Austrian R., et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New England Journal of Medicine 1991, 325(21):1453-1460.
26. Butler J.C., Breiman R.F., Campbell J.F., Lipman H.B., Broome C.V., Facklam R.R. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. Journal of the American Medical Association 1993, 270(15):1826-1831.
27. Rubins J.B., Alter M., Loch J., Janoff E.N. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infection and Immunity 1999, 67(11):5979-5984.
28. Robbins J.B., Austrian R., Lee C.J., et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. Journal of Infectious Diseases 1983, 148(6):1136-1159.
29. Poolman J., Kriz P., Feron C., et al. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccine 2009, 27(24):3213-3222.
30. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease after the introduction of protein polysaccharide conjugate vaccine. New England Journal of Medicine 2003, 348(18):1737-1746.
31. Lexau C.A., Lynfield R., Danila R., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. Journal of the American Medical Association 2005, 294(16):2043-2051.
32. Sahni V., Naus M., Hoang L., Tyrrell G.J., Martin I., Patrick D.M. The epidemiology of invasive pneumococcal disease in British Columbia following implementation of an infant immunization program: increases in herd immunity and replacement disease. Canadian journal of public health. Revue canadienne de santé publique 2012, 103(1):29-33.
33. Rosen J.B., Thomas A.R., Lexau C.A., et al. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clinical Infectious Diseases: 2011, 53(2):137-143.
34. Muhammad R.D., Oza-Frank R., Zell E., et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2013, 56(5):e59-e67.
35. Reinert R., Jacobs M.R., Kaplan S.L. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine 2010, 28(26):4249-4259.
36. Demczuk W.H., Martin I., Griffith A., et al. Serotype distribution of invasive Streptococcus pneumoniae in Canada during the introduction of the 13-valent pneumococcal conjugate vaccine, 2010. Canadian Journal of Microbiology 2012, 58(August (8)):1008-1017.
37. Weinberger D.M., Harboe Z.B., Flasche S., Scott J.A., Lipsitch M. Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. Epidemiology 2011, 22(2):199-207.
38. Sjostrom K., Spindler C., Ortqvist A., et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clinical Infectious Diseases 2006, 42(4):451-459.
39. Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clinical Infectious Diseases 2000, 30(1):100-121.
40. Fenoll A., Granizo J.J., Aguilar L., et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. Journal of Clinical Microbiology 2009, 47(4):1012-1020.
41. Pillai D.R., Shahinas D., Buzina A., et al. Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae. BMC Genomics 2009, 10:642.
42. van Hoek A.J., Andrews N., Waight P.A., et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. Journal of Infection 2012, 65(1):17-24. 3.
43. Hausdorff W.P., Feikin D.R., Klugman K.P. Epidemiological differences among pneumococcal serotypes. Lancet Infectious Diseases 2005, 5(2):83-93.
44. Harboe Z.B., Benfield T.L., Valentiner-Branth P., et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clinical Infectious Diseases 2010, 50(3):329-337.
45. Inverarity D., Lamb K., Diggle M., et al. Death or survival from invasive pneumococcal disease in Scotland: associations with serogroups and multilocus sequence types. Journal of Medical Microbiology 2011, 60(Pt. 6):793-802.
46. Harboe Z.B., Thomsen R.W., Riis A., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLOS Medicine 2009, 6(5 (April 17)):e1000081.
47. Flasche S., Slack M., Miller E. Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales. Euro Surveillance 2011, 16(20 (9)):19868.
48. McGeer A., Rudnick W., Wong K., et al. Evolution of Paediatric Invasive Pneumococcal Disease (IPD) after Implementation of a Routine Infant 13-valent Pneumococcal Conjugate Vaccination Program. Program and Abstracts for 2012 Annual Meeting of the Infectious Diseases Society of America 2012.
49. Thomas A., Reingold A., Harrison L., et al. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease U. S, 2010-11. Program and Abstracts for 2012 Annual Meeting of the Infectious Diseases Society of America 2012.
50. Levy C., Varon E., Bingen E., Béchet S., Cohen R. Effect of 7-valent and 13-valent Pneumococcal Conjugate Vaccines on Pneumococcal Meningitis in French Children under 2 years. Program and Abstracts of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy 2012.
51. Madhi S.A., Klugman K.P. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nature Medicine 2004, 10(8):811-813.